News
and Media
![Revolo News](https://revolobio.com/wp-content/uploads/news_media_newspaper@2x.png)
![](https://revolobio.com/wp-content/uploads/pink-circle-bg.png)
Press Releases and Media
July 24, 2024 | Press Release
Revolo Announces New Data Further Validating the Upstream Mechanism of Action and Subcutaneous Administration of ‘1104
GAITHERSBURG, MD and CAMBRIDGE, UK, July 24, 2024 /GlobeNewswire/ — Revolo Biotherapeutics Limited (“Revolo”) today announced new data from preclinical studies and previously completed clinical trials that further elucidate the upstream mechanism of action (MOA) of ‘1104, which uniquely affects both the effector and regulatory arms of the immune response. The data confirms that ‘1104 binds to a […]
May 14, 2024 | Press Release
Revolo Biotherapeutics to Present at Upcoming Medical Meetings in May
GAITHERSBURG, MD and CAMBRIDGE, UK, May 14, 2024 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior remission for patients with autoimmune and allergic diseases, today announced that it will present at two medical meetings in May: The American Thoracic Society (ATS) 2024 International Conference and […]
January 30, 2024 | Press Release
Revolo Biotherapeutics Receives Orphan Drug Designation from the U.S. FDA for its First-in-Class Peptide as a Potential Treatment for Eosinophilic Esophagitis
GAITHERSBURG, MD and CAMBRIDGE, UK, January 30, 2024 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ‘1104, a first-in-class […]